Intranasal Immunization of Guinea Pigs with an Immunodominant Foot-and-Mouth Disease Virus Peptide Conjugate Induces Mucosal and Humoral Antibodies and Protection against Challenge

Fischer, David D.; Rood, Debra; Barrette, Roger W.; ZuWallack, Alicia R.; Kramer, Ed; Brown, F.; Silbart, Lawrence K.

doi:10.1128/jvi.77.13.7486-7491.2003

Cited by 25 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When these VRPs were inoculated into mice and cotton rat intranasally, they elicited significant levels of hMPV-specific IgA antibodies in both the upper and lower respiratory tracts. Local virus-specific IgA secretion on the mucosal surfaces has been shown to be associated with protection of individuals from respiratory virus infections (17,19,26). Moreover, we detected systemic IgG antibodies against F or G antibodies in vaccinated animals.…”

Section: Discussionmentioning

confidence: 58%

An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

Mok

Tollefson²,

Podsiad³

et al. 2008

J Virol

View full text Add to dashboard Cite

Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that causes upper and lower respiratory tract infections in infants, the elderly, and immunocompromised individuals worldwide. Here, we developed Venezuelan equine encephalitis virus replicon particles (VRPs) encoding hMPV fusion (F) or attachment (G) glycoproteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice and cotton rats. VRPs encoding hMPV F protein, when administered intranasally, induced F-specific virus-neutralizing antibodies in serum and immunoglobulin A (IgA) antibodies in secretions at the respiratory mucosa. Challenge virus replication was reduced significantly in both the upper and lower respiratory tracts following intranasal hMPV challenge in these animals. However, vaccination with hMPV G protein VRPs did not induce neutralizing antibodies or protect animals from hMPV challenge. Close examination of the histopathology of the lungs of VRP-MPV F-vaccinated animals following hMPV challenge revealed no enhancement of inflammation or mucus production. Aberrant cytokine gene expression was not detected in these animals. Together, these results represent an important first step toward the use of VRPs encoding hMPV F proteins as a prophylactic vaccine for hMPV.

show abstract

Section: Discussionmentioning

confidence: 58%

An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

Mok

Tollefson²,

Podsiad³

et al. 2008

J Virol

View full text Add to dashboard Cite

show abstract

“…17 On the other hand, there is also evidence that the intrinsic disorder in certain loop regions at the surface of virus particles is responsible for the finding that peptides corresponding to such regions tend to give the best results as vaccine immunogens. [53][54][55] A good example of the hurdles that must be overcome to transform a continuous epitope into a vaccine immunogen is provided by the peptide ELDKWAS of the gp41 protein of HIV-1. This peptide which is recognized by the anti-HIV broadly neutralizing Mab 2F5 seemed a promising vaccine candidate and many groups have incorporated it into various immunogenic molecules to try to have it elicit antibodies with the same neutralizing capacity as Mab 2F5.…”

Section: Can Cross-protective Immunogenicity Of Peptides Be Predicted?mentioning

confidence: 99%

Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines

Regenmortel

2006

J of Molecular Recognition

102

View full text Add to dashboard Cite

“…This goal can be achieved by using a mucosal route for vaccination or possibly by use of a vaccine construct that preferentially induces mucosal responses. Protection in the upper respiratory tract has been demonstrated in several animal models (22,51) and in humans (42) following immunization by the intranasal (i.n.) route and has been linked to the induction of virus-specific mucosal immunoglobulin A (IgA) antibodies.…”

mentioning

confidence: 99%

Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats

Mok

Lee

Utley

et al. 2007

J Virol

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is an important viral pathogen that causes severe lower respiratory tract infection in infantsRespiratory syncytial virus (RSV) is a major human pathogen that causes serious lower respiratory tract illness in infants and the elderly. Significant morbidity and mortality for RSV are especially common in certain high-risk pediatric populations such as premature infants and infants with congenital heart or lung disorders. RSV bronchiolitis in infants is associated with recurrent wheezing and asthma later in childhood (53, 76). There are currently no FDA-approved vaccines for prevention of RSV disease by active immunization. Immunoprophylaxis by passive transfer of a humanized murine RSV fusion (F) protein-specific antibody is licensed for much of the high-risk infant population but is not cost-effective in otherwise healthy infants, who represent the majority of those hospitalized with RSV. There is also a high rate of RSV reinfection during childhood, which suggests that a protective immune response to a vaccine may need to differ either quantitatively or qualitatively from that induced by natural infection.Previous attempts to develop RSV vaccines have faced significant obstacles. An experimental formalin-inactivated RSV vaccine in the 1960s induced exacerbated disease and death in some vaccinated children during subsequent natural infection. It was shown subsequently that the formalin-inactivated RSV vaccine induced serum antibodies with poor neutralizing activity in infants (50) and an atypical Th2-biased T-cell response associated with enhanced histopathology following experimental immunization in small animals (58, 68). Treatment of RSV antigens with formaldehyde modifies the protein with carbonyl groups, which preferentially induces Th2-type responses and leads to enhanced disease (47). Other attempts to generate RSV vaccines include using live-attenuated cold-adapted, temperature-sensitive mutant strains of RSV (10, 12-17, 22, 32, 39, 41, 42), protein subunit vaccines coupled with adjuvant (30,56,70,73), and RSV proteins expressed from recombinant viral vectors, including vaccinia virus (52, 75), adenovirus (31), vesicular stomatitis virus (37), Semliki Forest virus (8), bovine/ human parainfluenza virus type 3 (26), Sendai virus (64), and Newcastle disease virus (45). Although some of these vaccines showed promising preclinical data, no vaccine has been licensed for human use due to safety concerns and lack of efficacy data. RSV vaccines under development have not been

show abstract

Intranasal Immunization of Guinea Pigs with an Immunodominant Foot-and-Mouth Disease Virus Peptide Conjugate Induces Mucosal and Humoral Antibodies and Protection against Challenge

Cited by 25 publications

References 41 publications

An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats

Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines

Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats

Contact Info

Product

Resources

About